Outcome of elderly patients with classical Hodgkin’s lymphoma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F20%3A73603529" target="_blank" >RIV/61989592:15110/20:73603529 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/20:10409558 RIV/00216208:11120/20:43919707 RIV/00216208:11150/20:10409558 RIV/00179906:_____/20:10409558 RIV/00064165:_____/20:10409558
Result on the web
<a href="https://www.sciencedirect.com/science/article/pii/S0145212620300163" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0145212620300163</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.leukres.2020.106311" target="_blank" >10.1016/j.leukres.2020.106311</a>
Alternative languages
Result language
angličtina
Original language name
Outcome of elderly patients with classical Hodgkin’s lymphoma
Original language description
Introduction The optimal management of elderly patients (pts) with Hodgkin's lymphoma is not yet defined. The aims of the present study were: 1) to evaluate clinical and laboratory characteristics of elderly pts; 2) to indentify risk factors for unfavorable outcome. Patients and methods The outcome of 182 pts ≥ 60 years (y) was retrospectively analyzed (median age, 67y). Mixed cellularity histology was diagnosed in 49.5 %, advanced stage of disease was in 68.7 % pts, CIRS > 3 in 35.7 %, ECOG PS ≥ 2 in 22.9 % (60-69y) of pts. Chemotherapy (CMT) alone was used in 69.2 % and combination of CMT and radiotherapy in 26.9 % of pts. Anthracycline-based CMT received 83.5 % of pts. The median follow-up was 4.5y. Results The overall response/complete remission rate was 85.6/70.7 %. The median progression free survival (PFS) and overall survival (OS) were 10y and 11.3y, respectively. Estimated 5-y PFS and 5-y OS were 65.7 % (in contrast to 98.2 % in pts < 60y; p < 0.001) and 70.5 % (99.4 % in pts < 60y; p < 0.001). Overall 70 (38.5 %) elderly pts died. The independent risk factors for a shorter OS included CIRS > 3, lymphopenia < 8 % and anthracycline-free CMT, for a shorter PFS anthracycline-free CMT and lymphopenia < 8 %. Conclusion CIRS > 3, lymphopenia < 8 % and anthracycline-free chemotherapy appear to be significant for unfavorable outcome.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
<a href="/en/project/NV16-29857A" target="_blank" >NV16-29857A: Cognitive impairment, structural and functional brain morphological sequelae of Hodgkin lymphoma treatment: Translational study.</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
LEUKEMIA RESEARCH
ISSN
0145-2126
e-ISSN
—
Volume of the periodical
90
Issue of the periodical within the volume
March 2020
Country of publishing house
GB - UNITED KINGDOM
Number of pages
7
Pages from-to
"'106311(1)'"-"'106311(7)'"
UT code for WoS article
000516786500005
EID of the result in the Scopus database
2-s2.0-85079048652